Related Experiment Video

Updated: Jun 15, 2026

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer

Elizabeth A Comen1, Mark Robson

  • 1Department of Medicine, Clinical Genetics and Breast Cancer Medicine Services, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

Oncology (Williston Park, N.Y.)
|March 2, 2010
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors are a targeted therapy for cancer. These drugs impair DNA repair, enhancing cancer cell death, particularly in BRCA-mutated or triple-negative breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer therapies are increasingly targeting specific molecular pathways.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors represent a novel class of targeted cancer drugs.
  • PARP enzymes are crucial for DNA damage repair, especially base excision repair (BER).

Purpose of the Study:

  • To review the role of PARP inhibition in breast cancer treatment.
  • To examine the mechanisms of action for PARP inhibitors.
  • To discuss current clinical trials and future directions for PARP inhibitors in oncology.

Main Methods:

  • Review of existing literature on PARP inhibitors and DNA repair pathways.
  • Analysis of preclinical and clinical data regarding PARP inhibitor efficacy.
  • Exploration of synthetic lethality as a mechanism of action.

Main Results:

  • PARP inhibition impairs DNA repair, enhancing cytotoxicity of DNA-damaging agents.
  • Synthetic lethality, particularly in BRCA-deficient cancers, is a key mechanism.
  • PARP inhibitors show promise in BRCA-associated and triple-negative breast cancer.

Conclusions:

  • PARP inhibitors offer a targeted therapeutic strategy for specific cancer types.
  • Understanding DNA repair mechanisms is critical for optimizing PARP inhibitor therapy.
  • Ongoing research and clinical trials are expanding the application of PARP inhibitors in cancer treatment.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...